Third-generation sequencing market seen topping $26.7B by 2030

The third-generation sequencing technology market is projected to climb from $14 billion in 2025 to $15.96 billion in 2026, as demand rises for precision medicine, clinical diagnostics and genomics research. The Business Research Company says the market could reach $26.71 billion by 2030, with North America leading global share in 2025.

Why it matters: - Third-generation sequencing is moving from a research tool into a broader clinical and precision medicine market. - Faster adoption could improve detection of structural variants, epigenetic changes and complex genomic regions that are harder to analyze with older sequencing methods. - The market’s growth signals rising demand for more detailed DNA and RNA analysis across research, diagnostics and personalized treatment.

What happened: - The Business Research Company released its Third-Generation Sequencing Technology Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report puts the market at $14 billion in 2025 and $15.96 billion in 2026, a 14.0% increase. - The report forecasts the market will reach $26.71 billion by 2030, implying a 13.7% CAGR over the forecast period. - North America held the largest share of the third-generation sequencing technology market in 2025. - The report also reviews Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report includes a free sample and the full market report.

The details: - Third-generation sequencing reads individual DNA or RNA molecules in real time. - The method often produces long, continuous reads without PCR amplification. - The technology is designed to generate high-accuracy genomic and transcriptomic data. - Key applications include detecting structural variants, epigenetic changes and complex genomic regions. - The historical growth outlook is tied to funding for genomics research, limits of short-read sequencing, adoption in academic research, rare disease studies and ongoing technological innovation. - Future growth is linked to precision medicine, clinical diagnostics, lower sequencing costs, AI analytics and population genomics programs. - Trends expected to shape the market include long-read sequencing, real-time DNA sequencing, clinical genomics, single-molecule sequencing and portable sequencing platforms. - Personalized medicine is a major demand driver because it uses genetic profiles to tailor treatment and prevention strategies. - The Personalized Medicine Coalition reported in February 2024 that the U.S. Food and Drug Administration approved 26 personalized medicines in 2023, up from 12 in 2022.

Between the lines: - The report points to a market shift where sequencing is becoming more practical for routine clinical use, not just advanced lab research. - Falling costs and AI integration could widen adoption, especially where clinicians need faster interpretation of complex genetic data. - North America’s lead suggests the region remains the center of commercial uptake, research funding and clinical adoption.

What's next: - The market is expected to keep expanding as more hospitals, research groups and diagnostics providers adopt long-read sequencing workflows. - Further gains will likely depend on how quickly clinical genomics, portable platforms and AI-driven analysis scale across regions. - Broader personalized medicine use should continue to support demand for sequencing tools and services.

The bottom line: - Third-generation sequencing is gaining momentum as a high-value technology for precision medicine, clinical diagnostics and advanced genomics research.